SCHEMBL29608393

SCHEMBL29608393

Cc1ccc(S(=O)(=O)n2cc(-c3ccc(C(=O)N4CC(O)C4)c(C)c3)c3nc(-c4cc(C)c5c(c4)CN(C)CC5)cnc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAP4K1 Q92918 3/20 0.49
▸ JAK2 O60674 5/20 0.36
▸ JAK1 P23458 5/20 0.36
▸ TYK2 P29597 5/20 0.36
▸ JAK3 P52333 5/20 0.36
▸ PTPN11 Q06124 1/20 0.35
▸ ALOX5AP P20292 1/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ KDM1A O60341 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ HCRTR1 O43613 1/20 0.30
▸ HCRTR2 O43614 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28865138 0.88 MAP4K1 (0.47) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL29607906 0.88 MAP4K1 (0.47) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL22859187 0.84 MAP4K1 (0.52) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL29607752 0.84 MAP4K1 (0.55) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL29911323 0.84 MAP4K1 (0.43) MAP4K1JAK1PTPN11KDM1A
SCHEMBL29608875 0.83 MAP4K1 (0.46) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL28701323 0.83 MAP4K1 (0.46) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL29608845 0.83 MAP4K1 (0.53) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL29609242 0.83 MAP4K1 (0.53) MAP4K1JAK2JAK1TYK2JAK3
SCHEMBL28717414 0.82 MAP4K1 (0.43) MAP4K1PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof BEONE MEDICINES I GMBH (CH) 2025-10-28 — — US disclosed
CN-115073474-A Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-09-20 — — CN disclosed
CN-115028639-A Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-09-09 — — CN disclosed
US-20220267333-A1 PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2022-08-25 — — US disclosed
EP-3994136-A1 PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BeiGene, Ltd. (KY) 2022-05-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267333-A1 PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF PDXK, STK25, STK35 MAP4K1 82/4885JAK2 453/4885JAK1 714/4885
US-12454534-B2 Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof PDXK, STK25, STK35 MAP4K1 82/4885JAK2 453/4885JAK1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback